SYDNEY , April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced...
SYDNEY, Australia , April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment...
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression
SYDNEY , Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and...
SYDNEY , Jan. 8, 2026 /PRNewswire/ --Â Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings...
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength
First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters
SYDNEY , Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) , an oncology-focused drug development company, today announced that it has entered into a securities purchase...
SYDNEY , Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast...
SYDNEY , Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug...